Ligand Pharmaceuticals LGND CECL adjustment to financial royalty assets
CECL adjustment to financial royalty assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:CurrentAndExpectedCreditLossAdjustment.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's cecl adjustment to financial royalty assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's CECL adjustment to financial royalty assets?
- Ligand Pharmaceuticals (LGND) reported CECL adjustment to financial royalty assets of $21K in Q1 2026.
- How has Ligand Pharmaceuticals's CECL adjustment to financial royalty assets changed year-over-year?
- Ligand Pharmaceuticals's CECL adjustment to financial royalty assets increased by 106.4% year-over-year, from -$330K to $21K.
- What does CECL adjustment to financial royalty assets mean?
- This represents the non-cash charge or reversal related to the Current Expected Credit Loss (CECL) model applied to financial royalty assets or receivables. It reflects management's estimate of potential future credit losses based on current economic conditions and historical data. This metric is a key indicator of the perceived credit risk associated with the company's royalty-based assets.